Answers are grounded in this paper and cite their sources.
Study question What is the expression dynamic of glucagon-like peptide-1 receptor (GLP-1R) in human endometrium, and how does GLP-1R agonist (GLP-1RA-semaglutide) influence endometrial maturation and embryo development? Summary answer GLP-1R was predominantly expressed during the mid-secretory phase. Semaglutide induced dynamic, dose-dependent transcriptomic changes in endometrial epithelial organoids (EEOs), primary stromal cells (ESCs), and blastoids. What is known already Semaglutide, a GLP-1RA, has proven effective in improving glycaemic control and is an emerging therapeutic option for type 2 diabetes, obesity and polycystic ovarian syndrome (PCOS). Based on preclinical studies, GLP-1RA therapy has shown the potential to alleviate female infertility, primarily by restoring ovulation. However, the expression landscape of GLP-1R in the endometrium and embryo, as well as the effects of GLP-1RA therapy on embryo development, remain largely unknown. Investigating the impact of GLP-1RA on in vitro modern endometrial models and embryo-like blastoids could provide valuable insights into its potential influence on endometrial receptivity and implantation. Study design, size, duration GLP-1R expression was determined in endometrial tissues from fertile women across menstrual cycle phases (n = 20). Paired primary ESCs and EEOs were derived from endometrial biopsies (n = 4) from fertile women and were hormonally stimulated with oestradiol (E2), progesterone (P) and Cyclic adenosine monophosphate (cAMP) to achieve receptive status (6 days) and decidualization (9 days) in parallel with and without semaglutide treatment. The H9 cell line was used for blastoid generation. Participants/materials, setting, methods The expression of GLP-1R in endometrium was determined by immunohistochemistry. ESCs and EEOs were exposed to semaglutide according to pharmacokinetics (39 nM, 1.25 μM and 5 μM) and evaluated with resazurin assay for cell viability. Semaglutide-treated endometrial cells were subjected to a cAMP biosensor assay. The decidualization of ESC cells was assessed by prolactin ELISA assay from spent culture media. RNA from ESCs, EEO and blastoid was subjected to library preparation and sequencing using NextSeq1000. Main results and the role of chance GLP1R was expressed in the human endometrium throughout the menstrual cycle, with the highest expression in the mid-secretory phase. We observed a significant (P < 0.05) dose-dependent decrease in the metabolic capacity of viable ESCs in response to increasing semaglutide concentration whereas in EEOs, cell viability was significantly reduced after exposure to 5μM. ESCs and EEOs (treated with E2 and E2P) showed dose-dependent cAMP production, significantly increasing at 5μM exposure (P < 0.05). In ESCs, the decidualization was confirmed by prolactin assay, and in EEO, the endometrial receptivity-associated genes were upregulated in the transcriptome profile (PAEP, LIF, SPP1). Treatment with 39 nM semaglutide did not affect the transcriptome of the endometrial cells, while 1.25 μM had 10 DEGs. Treatment with 5 μM semaglutide significantly altered the transcriptomes of EEOs and ESCs (adjusted P < 0.05). In EEOs, over 400 DEGs were identified, mainly linked to metabolic processes, mitochondrial function, and endometrial receptivity. In ESCs, semaglutide primarily affected cell cycle-related genes, notably downregulating cell proliferation (adjusted P < 0.05). The blastoid transcriptome in all concentrations revealed upregulation of genes associated with regulation of pluripotent stem cells and endoderm differentiation (EPAS1, PBX1, TDGF1, PRDM14, SOX2) while it downregulated metabolic processes. Limitations, reasons for caution This in vitro study provides important insights into the impact of semaglutide on underlying mechanisms of endometrial maturation and embryo development. Further evaluation of the semaglutide effect in obese and PCOS women is required for translational relevance. The study does not claim clinical safety and efficacy for therapeutic use. Wider implications of the findings The study underscores the fundamental mechanistic effects of semaglutide on EEOs, ESCs, and blastoids which could be used to explore its impact on female fertility mediating endometrium-embryo interactions. On confirming the safety of GLP-1RAs and lack of teratogenic potential, its use could revolutionize the personalized treatment of female infertility. Trial registration number No
No takes yet. Share an insight, caveat, or question.
Pathare et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: